Women’s health: Robinson said segment revenue rose 25% in FY25, with NEXTSTELLIS supported by demand cycle growth and higher net sales year-on-year. Gray reported NEXTSTELLIS demand cycles grew 30% and the licensed women’s health portfolio grew 17%. Gray reported NEXTSTELLIS demand cycles grew 30% and the licensed women’s health portfolio grew 17%. Unaudited underlying EBITDA was AUD 28.6 million, down 8%, which Gray attributed primarily to planned women’s health commercial investment and timing of costs. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.